Comparative Pharmacology
Head-to-head clinical analysis: MEGACE ES versus NORLUTATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MEGACE ES versus NORLUTATE.
MEGACE ES vs NORLUTATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Megestrol acetate is a synthetic progestin that inhibits pituitary gonadotropin secretion, leading to suppression of ovarian and testicular hormone production. It also has antineoplastic effects possibly through local action on hormone-sensitive tissues and stimulates appetite via modulation of neuropeptide Y and other appetite-regulating factors.
Progestin that suppresses gonadotropin secretion, inhibits ovulation, and induces endometrial transformation.
625 mg orally once daily (MEGACE ES suspension contains 625 mg/5 mL; shake well before use). For appetite stimulation in cachexia.
5 mg orally once daily for 5 days, starting on day 1 of menstrual cycle; for menorrhagia, 5 mg orally three times daily from day 19 to day 26 of cycle.
None Documented
None Documented
Approximately 34 hours in plasma; steady-state achieved after 2-3 weeks of daily dosing.
Terminal elimination half-life is approximately 5-6 hours. Clinical context: supports twice-daily dosing; steady state reached within 2 days.
Primarily renal (≤1% unchanged) and biliary; extensive metabolism to inactive glucuronide conjugates excreted in feces.
Primarily renal (approximately 60% of metabolites, mostly glucuronides), with about 40% fecal/biliary elimination. Less than 1% excreted unchanged.
Category C
Category C
Progestin
Progestin